Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daptomycin vs SOC in Pediatric S. aureus Bacteremia
NCT01728376Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2012
- Primary completion
- Jan 2016
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
01
Overview
A Phase 4 trial of daptomycin in Staphylococcus aureus bacteremia (SAB), sponsored by Merck & Co.. Started Nov 2012; status: completed.
02
Drugs
daptomycin
03
Conditions
Staphylococcus aureus bacteremia (SAB)
Beyond the preview
Go deeper on NCT01728376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01728376.